[go: up one dir, main page]

IN2014DN03464A - - Google Patents

Download PDF

Info

Publication number
IN2014DN03464A
IN2014DN03464A IN3464DEN2014A IN2014DN03464A IN 2014DN03464 A IN2014DN03464 A IN 2014DN03464A IN 3464DEN2014 A IN3464DEN2014 A IN 3464DEN2014A IN 2014DN03464 A IN2014DN03464 A IN 2014DN03464A
Authority
IN
India
Prior art keywords
providing neuroprotection
stroke
mirna
administering
variant
Prior art date
Application number
Other languages
English (en)
Inventor
Suh hang H JUO
Yung Song Wang
Hsin Yun Cheng
Original Assignee
Dcb Usa Llc
Univ Kaohsiung Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dcb Usa Llc, Univ Kaohsiung Medical filed Critical Dcb Usa Llc
Publication of IN2014DN03464A publication Critical patent/IN2014DN03464A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
IN3464DEN2014 2011-11-03 2012-11-05 IN2014DN03464A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555152P 2011-11-03 2011-11-03
PCT/US2012/063604 WO2013067531A2 (fr) 2011-11-03 2012-11-05 Méthodes d'utilisation de micro-arn 195 pour la neuroprotection

Publications (1)

Publication Number Publication Date
IN2014DN03464A true IN2014DN03464A (fr) 2015-06-05

Family

ID=48193054

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3464DEN2014 IN2014DN03464A (fr) 2011-11-03 2012-11-05

Country Status (7)

Country Link
US (1) US9315812B2 (fr)
EP (1) EP2773381B1 (fr)
JP (1) JP5888572B2 (fr)
CN (1) CN104080910A (fr)
IN (1) IN2014DN03464A (fr)
TW (1) TWI462741B (fr)
WO (1) WO2013067531A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916989A1 (fr) * 2013-06-28 2014-12-31 London Health Sciences Centre Research Inc. Inhibition du micro-arn pour le traitement de la septicemie
CN106474549B (zh) 2016-11-21 2019-05-03 南通大学 MicroRNA基因介导的新型组织工程化神经的构建及其在修复神经缺损的应用
WO2018111784A1 (fr) * 2016-12-14 2018-06-21 China Medical University Compositions de micro-arn 195 et leur utilisation thérapeutique dans des maladies oculaires
EP4100021A4 (fr) * 2020-02-03 2023-11-15 Rutgers, the State University of New Jersey Compositions de micro-arn-7 destinées à favoriser la récupération fonctionnelle à la suite d'un traumatisme médullaire et leurs procédés d'utilisation
WO2022033529A1 (fr) * 2020-08-12 2022-02-17 洪明奇 Utilisation d'un antagoniste de sema3d dans la prévention ou le traitement de maladies neurodégénératives et prolongeant la durée de vie
CN113599540B (zh) * 2021-05-27 2023-05-23 山西医科大学 miRNA-195-5p在制备抑制或降低麦芽酚铝所致神经细胞损伤的试剂中的应用
CN113308535A (zh) * 2021-06-11 2021-08-27 中国人民解放军空军军医大学 一种基于血清外泌体miRNA的PD诊断及分期试剂盒
CN116590403B (zh) * 2023-05-17 2024-11-22 华中科技大学同济医学院附属同济医院 血浆外泌体microRNA novel-3及其拮抗剂和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP2530157B1 (fr) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Composés oligomères et compositions à utiliser dans la modulation de miARNs
EP2295604B1 (fr) * 2004-02-09 2015-04-08 Thomas Jefferson University Diagnostic et traitement de cancers à l'aide de microARN présent dans ou au voisinage de caractéristiques chromosomiques associées aux cancers
US20100298407A1 (en) * 2007-01-17 2010-11-25 The Johns Hopkins University Compositions and methods featuring micronas for treating neoplasia
CA2705325C (fr) * 2007-11-09 2016-11-01 The Board Of Regents Of The University Of Texas System Micro-arn de la famille mir-15 modulant la survie de cardiomyocytes et la reparation cardiaque
US20110117111A1 (en) * 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
EP2112235A1 (fr) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions et procédés pour le profilage de l'expression de microARN du carcinome du nasopharynx
EP2239675A1 (fr) * 2009-04-07 2010-10-13 BIOCRATES Life Sciences AG Procédé pour le diagnostic in vitro d'une maladie complexe
WO2010151640A2 (fr) * 2009-06-24 2010-12-29 Board Of Regents Of The University Of Nebraska Compositions et procédés pour le diagnostic et le traitement de troubles inflammatoires et de maladie fibreuse
US8354520B2 (en) * 2009-12-10 2013-01-15 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug

Also Published As

Publication number Publication date
US20140294943A1 (en) 2014-10-02
WO2013067531A3 (fr) 2014-07-03
JP2014533248A (ja) 2014-12-11
JP5888572B2 (ja) 2016-03-22
EP2773381A4 (fr) 2015-07-08
EP2773381A2 (fr) 2014-09-10
CN104080910A (zh) 2014-10-01
TWI462741B (zh) 2014-12-01
TW201322987A (zh) 2013-06-16
WO2013067531A2 (fr) 2013-05-10
EP2773381B1 (fr) 2020-06-03
US9315812B2 (en) 2016-04-19

Similar Documents

Publication Publication Date Title
IN2014DN03464A (fr)
MX2019011905A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
EP2757887A4 (fr) Composés pyrrolopyridinones et méthodes de traitement du vih
MX364495B (es) Composición para usarse en el tratamiento de enfermedades oculares relacionadas con ácidos nucleicos.
MX2013004570A (es) Mezclas fungicidas de penflufen.
SMT202100325T1 (it) Metodi e composizioni per l’inibizione specifica della glicolato ossidasi (hao1) mediante rna a doppio filamento
IN2012MU03723A (fr)
PL2763527T3 (pl) Sposób obróbki grzybobójczej odpornych szczepów przy użyciu jednego lub więcej olejków eterycznych
EP2677068A4 (fr) Procédé de traitement de surface d'un élément métallique et élément métallique ainsi obtenu
ZA201306990B (en) Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
PL2997173T3 (pl) Sposób wytwarzania stali powleczonej cynkiem do utwardzania w procesie tłoczenia na gorąco
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
EP2758780A4 (fr) Méthode de traitement de la sclérose en plaques
IN2015DN02292A (fr)
ZA201404327B (en) Composition comprising block cocondensates of propylfunctional alkaline siliconates and silicates, and method for the production thereof
IN2014DN08777A (fr)
EP2739332A4 (fr) Obturateur/piston pour carpules d'ensemble seringue-carpule
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
ZA201408975B (en) Method of treating scedosporium spp. infection
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
HUE038149T2 (hu) Eljárás acél kezelésére
PT2694065T (pt) Placas de assentamento melhoradas
PL2768527T3 (pl) Wieloważna szczepionka przeciw CBV do zapobiegania lub leczenia cukrzycy typu 1
IN2013CH05865A (fr)
PT2678015E (pt) Utilização de nifuratel para tratar infecções por espécies de clostridium